Novo Nordisk (NVO) ended the recent trading session at $75.89, demonstrating a +1.47% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss of ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

A produtora do Ozempic, Novo Nordisk, planeja fabricar mais medicamentos para o mercado dos Estados Unidos localmente; a ...

Dow, S&P 500, and Nasdaq futures are falling in premarket trading Thursday as the stock market digests CPI inflation data and braces for Trump's response to Canada and EU tariffs.

Apollo Global Management, Novo Nordisk A/S, BlackRock, Blackstone, and Prologis are the five Growth stocks to watch today, according to MarketBeat’s stock screener tool. Growth stocks are shares of ...

Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.

Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...